K
Kenta Noda
Researcher at Sysmex Corporation
Publications - 8
Citations - 167
Kenta Noda is an academic researcher from Sysmex Corporation. The author has contributed to research in topics: Immunoassay & Antigen. The author has an hindex of 3, co-authored 8 publications receiving 39 citations.
Papers
More filters
Journal ArticleDOI
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: In this article, the authors examined the effect of BNT162b2-elicited SARS-CoV-2 neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants and the potency of sera against variants of concerns.
Journal ArticleDOI
A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies.
Kenta Noda,Kouki Matsuda,Shigehiro Yagishita,Kenji Maeda,Yutaro Akiyama,Junko Terada-Hirashima,Hiromichi Matsushita,Satoshi Iwata,Kazuto Yamashita,Yusuke Atarashi,Shunsuke Watanabe,Nobuyuki Ide,Tomokazu Yoshida,Norio Ohmagari,Hiroaki Mitsuya,Hiroaki Mitsuya,Akinobu Hamada +16 more
TL;DR: In this article, the authors developed a diagnostic test that detects SARS-CoV-2 IgG and IgM with high quantitativeness and reproducibility and low interference.
Journal ArticleDOI
Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.
Megumi Goto,Kenji Chamoto,Keiko Higuchi,Saya Yamashita,Kenta Noda,Iino Takuya,Masahiro Miura,Toshinari Yamasaki,Osamu Ogawa,Makoto Sonobe,Hiroshi Date,Junzo Hamanishi,Masaki Mandai,Yoshimasa Tanaka,Shunsuke Chikuma,Ryusuke Hatae,Manabu Muto,Sachiko Minamiguchi,Nagahiro Minato,Tasuku Honjo +19 more
TL;DR: Application of this rapid and sensitive immunoassay system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types.
Journal ArticleDOI
The utility of urinary CD80 as a diagnostic marker in patients with renal diseases.
Shogo Minamikawa,Kandai Nozu,Shingo Maeta,Tomohiko Yamamura,Keita Nakanishi,Junya Fujimura,Tomoko Horinouchi,China Nagano,Nana Sakakibara,Hiroaki Nagase,Hideaki Shima,Kenta Noda,Takeshi Ninchoji,Hiroshi Kaito,Kazumoto Iijima +14 more
TL;DR: The results suggest that urinary CD80 is unreliable as a differential diagnostic marker between MCD in relapse and FSGS or inherited kidney diseases, and increased urinaryCD80 excretion was present in all patients with active kidney disease.
Journal ArticleDOI
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19.
Takehiro Hasegawa,Atsushi Nakagawa,Kohjin Suzuki,Kazuto Yamashita,Saya Yamashita,Niina Iwanaga,Eiya Tamada,Kenta Noda,Keisuke Tomii +8 more
TL;DR: In this paper, the authors investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes, and found that patients with high levels of Type 1 (T1) inflammatory markers frequently suffered from tissue damage, manifested as ARDS and AKI.